Phase 3Completed
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)
A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less
- Sponsor
- Amgen (Industry)
- Enrollment
- 615 enrolled
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab; Ezetimibe; Placebo to Evolocumab; Placebo to Ezetimibe
- Ages
- adults, older adults
- Registry
- NCT01763827
Full record on ClinicalTrials.gov
From the registry
The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.
Primary outcomes
- Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
- Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
History
Last registry update
Results first posted
Study completion
Primary completion
Started
Registered